EXAI / Exscientia: Direct Exposure To AI Integration To Drug Discovery, Development

RKDA, GHRS, GPS, RITM and EXAI have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2023. more_horizontal

Exscientia PLC Sponsored ADR (EXAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revision more_horizontal

Exscientia PLC Sponsored ADR (EXAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with stro more_horizontal

Exscientia plc has partnered with Merck KGaA for AI-powered drug discovery in complex disease segments, solidifying its industry positioning. AI is ga more_horizontal

Exscientia PLC shares climbed as much as 30% in pre-market trading on Wednesday after the precision-medicine company announced a new, multi-year coll more_horizontal

The U.S.-listed shares of Exscientia PLC EXAI soared 28.5% toward a record one-day gain, and enough to pace all premarket gainers on major U.S. exchan more_horizontal

Med tech stocks are ripe for growth due to the advent of artificial intelligence ( AI ). AI is going to improve healthcare overall. more_horizontal

Many investors, including a significant number of very wealthy individuals and institutions, are becoming enthralled with AI stocks. According to Gold more_horizontal